Cidara Therapeutics, Inc.

Company Overview

Business Model: Cidara Therapeutics, Inc. is a biotechnology company focused on developing drug-Fc conjugate (DFC) immunotherapies using its proprietary Cloudbreak platform. These DFCs are designed to provide potent disease targeting activity and immune system engagement in a single, long-acting molecule, aiming to treat and prevent serious diseases such as viral infections and solid tumors. The company's current revenue is primarily derived from collaboration agreements, with future potential from license fees, upfront payments, funded research and development (R&D) agreements, milestone payments, product sales, government funding, and royalties.

Market Position: Cidara Therapeutics, Inc. positions its Cloudbreak platform as a novel approach distinct from existing therapies like antibody drug conjugates (ADCs), monoclonal or multi-specific antibodies, and vaccines. Its lead clinical-stage asset, CD388, a DFC for influenza prophylaxis, has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for high-risk adults. The company operates in a highly competitive biopharmaceutical industry, facing competition from larger, better-funded pharmaceutical and biotechnology companies.

Recent Strategic Developments:

• CD388 Reacquisition: In April 2024, Cidara Therapeutics, Inc. reacquired all worldwide rights to develop and commercialize CD388 from J&J Innovative Medicine (previously Janssen Pharmaceuticals, Inc.). This reacquisition was funded by an $85.0 million upfront payment from a $240.0 million private placement.
• Rezafungin Divestment: Concurrent with the CD388 reacquisition in April 2024, Cidara Therapeutics, Inc. divested all rezafungin assets to Napp Pharmaceutical Group Limited, including rights to future milestones and royalties from Melinta Therapeutics, LLC and Mundipharma Medical Company. This move streamlines the company's portfolio to focus solely on the Cloudbreak platform.
• Capital Raises: The company completed two private placements in 2024: $240.0 million gross proceeds from the sale of Series A Convertible Voting Preferred Stock in April 2024, and $105.0 million gross proceeds from the sale of common stock and pre-funded warrants in November 2024.
• CD388 Clinical Advancement: The CD388 Phase 2b NAVIGATE study was initiated in September 2024 and reached full planned enrollment of at least 5,000 subjects across clinical trial sites in the United States and the United Kingdom by December 2024. Topline data is expected in the third quarter of 2025, with a potential early analysis in the first half of 2025.
• CBO421 IND Clearance: CBO421, a lead oncology DFC candidate targeting CD73 for solid tumors, received investigational new drug application (IND) clearance in July 2024.
• Workforce Reduction: In September 2024, Cidara Therapeutics, Inc. approved a reduction in its workforce of 20 employees (approximately 30%) to align with its focused clinical development strategy for CD388.

Geographic Footprint: Cidara Therapeutics, Inc. primarily operates in the U.S. and has wholly-owned subsidiaries, Cidara Therapeutics UK Limited in England and Cidara Therapeutics (Ireland) Limited in Ireland, for developing product candidates in Europe. The CD388 Phase 2b NAVIGATE study is being conducted in the United States and the United Kingdom.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: Not applicable (revenue is collaboration-based, no cost of goods sold reported for continuing operations).
• Operating Margin: -13546.2%
• Net Margin: -13061.5%

Investment in Growth:

• R&D Expenditure: $71.9 million (5530.8% of revenue)
• Capital Expenditures: $0.1 million
• Strategic Investments: $85.0 million upfront payment for the reacquisition of CD388 rights from J&J Innovative Medicine.

Business Segment Analysis

Cidara Therapeutics, Inc. manages its business as a single reportable segment, with its R&D efforts focused on the Cloudbreak platform across distinct programs.

Cloudbreak Influenza Program (CD388)

Financial Performance:

• R&D Expenditure (Cloudbreak platform): $56.5 million (+118.1% YoY)
• Key Growth Drivers: The significant increase in R&D expenses is primarily driven by the advancement of CD388 into the Phase 2b NAVIGATE study. CD388 is a highly potent antiviral DFC designed for universal prevention and treatment of seasonal and pandemic influenza.

Product Portfolio:

• CD388: A drug-Fc conjugate (DFC) for influenza prophylaxis.
• New product launches or major updates: The CD388 Phase 2b NAVIGATE study was initiated in September 2024 and achieved full enrollment of at least 5,000 subjects by December 2024. Topline data is anticipated in Q3 2025, with a potential for an early analysis in H1 2025.

Market Dynamics:

• Competitive positioning within segment: CD388 is being developed to offer broad-spectrum, universal coverage against influenza A and B, a superior resistance profile, protection for high-risk populations independent of immune status, rapid onset, and long duration of action (months of protection from a single dose). It aims to differentiate from existing seasonal vaccines and antiviral drugs.
• Key customer types and market trends: Targets individuals who could benefit from a long-acting, universal preventative against influenza, particularly those at high risk of complications or who may not respond adequately to vaccines.

Cloudbreak Oncology Programs (CBO421)

Financial Performance:

• R&D Expenditure (Cloudbreak platform): Included within the overall Cloudbreak platform R&D, not separately disaggregated.
• Key Growth Drivers: Focus on discovering and developing highly potent DFCs that can target single or multiple immune checkpoint pathways for the treatment of solid tumors.

Product Portfolio:

• CBO421: A lead oncology DFC candidate, a highly differentiated CD73 inhibitor for the treatment of solid tumors. Received IND clearance in July 2024.
• New product launches or major updates: Cidara Therapeutics, Inc. does not currently plan to initiate clinical trials for oncology product candidates but is actively pursuing business development discussions for these programs, including CBO421.

Market Dynamics:

• Competitive positioning within segment: CBO421 aims to improve response rates to immunotherapy by targeting the CD73 pathway, which contributes to immune evasion in solid cancers. Preclinical data indicates activity as monotherapy and in combination with PD-1 inhibitors in murine tumor models, with differentiated activity in T-cell reactivation assays and tumor penetration.
• Key customer types and market trends: Targets solid tumor cancers, including triple negative breast cancer (TNBC) and other solid tumors that have limited response to existing checkpoint inhibition therapies.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: None reported for the years ended December 31, 2024 and 2023.
• Dividend Payments: Cidara Therapeutics, Inc. does not anticipate declaring or paying any cash dividends in the foreseeable future, intending to retain all available funds for business development, operation, and expansion.
• Dividend Yield: Not applicable.
• Future Capital Return Commitments: No authorized share repurchase programs or dividend commitments disclosed.

Balance Sheet Position:

• Cash and Equivalents: $189.8 million (as of December 31, 2024)
• Total Debt: None (no outstanding loan balances as of December 31, 2024).
• Net Cash Position: $189.8 million (as of December 31, 2024)
• Credit Rating: Not disclosed.
• Debt Maturity Profile:
  • Finance Lease Liabilities: Total undiscounted payments of $0.6 million as of December 31, 2024, with $0.3 million due in 2025 and $0.3 million in 2026.
  • Operating Lease Liabilities: Total undiscounted payments of $3.4 million as of December 31, 2024, with $1.7 million due in 2025 and $1.7 million in 2026.

Cash Flow Generation:

• Operating Cash Flow: -$176.5 million (2024) vs. -$22.4 million (2023)
• Free Cash Flow: -$176.6 million (2024) vs. -$22.9 million (2023)
• Cash Conversion Metrics: Not explicitly detailed in the filing.

Operational Excellence

Production & Service Model: Cidara Therapeutics, Inc. does not own or operate any manufacturing facilities and relies entirely on third-party contract manufacturers for the production of its product candidates for preclinical studies, clinical trials, and future commercial supply. The company's third-party contract manufacturers are expected to utilize reliable and reproducible processes and common manufacturing techniques.

Supply Chain Architecture: Key Suppliers & Partners:

• Contract Manufacturers: Cidara Therapeutics, Inc. relies on third-party contract manufacturers for the production of its product candidates.
• Single-Source Suppliers: Some materials for product candidates may be sourced from single-source suppliers.
• Geographic Exposure: Some manufacturers and suppliers are located in China, which exposes the company to potential trade restrictions and geopolitical risks.

Facility Network:

• Administrative, Research & Development: Cidara Therapeutics, Inc. leases a 29,638 square foot facility in San Diego, California, for administrative, research, and development activities. The current lease expires in December 2026, with options for two additional two-year terms.
• Manufacturing: No owned manufacturing facilities.
• Research & Development: R&D activities are conducted at the San Diego facility.

Operational Metrics: No specific operational metrics such as capacity utilization, efficiency measures, or quality indicators were disclosed in the filing.

Market Access & Customer Relationships

Go-to-Market Strategy: Cidara Therapeutics, Inc. currently lacks a sales or marketing infrastructure. Its strategy for commercial success, if any product candidates are approved, involves either licensing rights to third parties with established capabilities or developing its own sales and marketing organization.

Customer Portfolio: Enterprise Customers:

• Strategic Partnerships: The company has previously engaged in strategic partnerships with J&J Innovative Medicine (formerly Janssen Pharmaceuticals, Inc.), Napp Pharmaceutical Group Limited, Mundipharma Medical Company, and Melinta Therapeutics, LLC for the development and commercialization of its assets.
• Customer Concentration: No specific customer concentration metrics or top customer percentages were disclosed for continuing operations.

Geographic Revenue Distribution:

• United States: 100% of total collaboration revenue from continuing operations was generated in the U.S. for the years ended December 31, 2024 and 2023.
• Growth Markets: No specific emerging market initiatives or performance details were disclosed.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The biopharmaceutical industry is characterized by intense and dynamic competition in developing new technologies and proprietary therapies. Regulatory incentives for infectious disease treatments have increased activity and competition for clinical investigators, trial subjects, and future prescriptions. Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• For CD388 (Influenza): Cidara Therapeutics, Inc. expects CD388 to compete against approved and investigational influenza vaccines, monoclonal antibodies targeting hemagglutinin, and small molecule neuraminidase inhibitors such as Tamiflu, Relenza, and Peramivir, as well as endonuclease inhibitors like Xofluza.
• For CBO421 (Oncology): CBO421 is expected to compete against approved anticancer therapeutics, investigational CD73-targeting small molecule drugs (e.g., quemliclustat by Arcus Biosciences, Inc.), and monoclonal antibodies (e.g., oleclumab by AstraZeneca PLC).

Emerging Competitive Threats: The company faces potential threats from new market entrants, disruptive technologies, and alternative solutions in the rapidly evolving biopharmaceutical industry.

Competitive Response Strategy: Cidara Therapeutics, Inc. aims to leverage its scientific and development expertise in anti-infectives and the Cloudbreak platform to develop differentiated product candidates. The company's DFCs are designed to offer multimodal mechanisms of action, strong target binding, and long duration of action, potentially providing advantages over existing and emerging therapies.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics:

• Competition: Intense and dynamic competition from larger, better-funded pharmaceutical and biotechnology companies, as well as academic and research institutions. Competitors may develop more effective, safer, or cheaper products, or obtain regulatory approval sooner.
• Technology Disruption: Risk of competitors inventing technology that competes with the Cloudbreak platform or renders product candidates obsolete.
• Market Acceptance: Any approved product candidates may fail to achieve sufficient market acceptance by physicians, patients, formulary committees, and third-party payors.
• Global Economic Conditions: Unfavorable global economic conditions, including volatility in financial markets, inflation, bank failures, labor shortages, supply chain disruptions, recession risks, and geopolitical conflicts (e.g., Russia-Ukraine, Israel-Hamas war), could adversely affect business, funding, and operations.

Operational & Execution Risks

Supply Chain Vulnerabilities:

• Third-Party Manufacturing Dependence: Reliance on third-party manufacturers for all product candidates, with no internal manufacturing experience. Risks include regulatory non-compliance, breach of agreements, termination of agreements, and inability to meet quality standards or deadlines.
• Single-Source Supplier Dependency: Some materials may be sourced from single-source suppliers, posing risks if a supplier is unable to perform.
• Geographic Concentration: Dependence on manufacturers and suppliers in China exposes the company to geopolitical unrest, trade restrictions, and potential supply disruptions.
• Capacity Constraints: Potential for delays or insufficient supply if manufacturers cannot perform as agreed or if alternative manufacturers are needed, requiring new approvals and testing. Clinical Trial Execution:
• Enrollment Delays: Difficulties in enrolling and retaining patients in clinical trials could delay or prevent regulatory approvals, increase costs, and shorten patent protection periods.
• Trial Outcomes: Clinical trials may be delayed, terminated, suspended, or fail to demonstrate safety and efficacy, leading to additional costs or inability to complete development.
• Adverse Reactions: Identification of serious adverse reactions or unexpected characteristics during development may necessitate abandoning or limiting product candidate development. Information Technology & Data Security:
• Cybersecurity Threats: Vulnerability to cyberattacks, malicious activity, fraud, and other security incidents that could compromise information technology systems and sensitive data (intellectual property, clinical trial data, employee data).
• Third-Party IT Reliance: Reliance on third parties for critical business systems and data processing introduces additional cybersecurity risks, including supply-chain attacks.
• Data Privacy & Security Compliance: Subject to stringent and evolving U.S. and foreign laws (e.g., Health Insurance Portability and Accountability Act of 1996, California Consumer Privacy Act of 2018, EU’s General Data Protection Regulation) and contractual obligations, with non-compliance leading to investigations, fines, litigation, and reputational harm.
• AI/ML Risks: Use of AI and machine learning (ML) to assist in decision-making could lead to biased outcomes or compliance costs if not properly managed.

Financial & Regulatory Risks

Funding & Profitability:

• Need for Additional Funding: Requires substantial additional funding to advance CD388 beyond Phase 2b and other Cloudbreak programs. Inability to raise capital on acceptable terms could force delays, reductions, or termination of development programs.
• Operating Losses: History of significant operating losses and anticipated continued losses for the foreseeable future, with no assurance of achieving or maintaining profitability.
• Dilution: Future capital raises through equity or convertible debt will dilute existing stockholders' ownership. Regulatory & Compliance Risks:
• Approval Delays/Failures: Inability to obtain or delays in obtaining required regulatory approvals (e.g., FDA, foreign authorities) would impair revenue generation.
• Post-Approval Restrictions: Approved products may face marketing restrictions, withdrawal from the market, or penalties for non-compliance with regulatory requirements.
• Healthcare Laws: Relationships with customers, healthcare professionals, and third-party payors are subject to anti-kickback laws, false claims laws, and data privacy laws, exposing the company to penalties for non-compliance.
• Healthcare Reform: Current and future legislative proposals (e.g., Affordable Care Act, Inflation Reduction Act of 2022) could reduce reimbursement, increase costs, or delay approvals.
• Foreign Regulation: Compliance with numerous and varying regulatory requirements in other countries, including potential price controls and data localization laws, could delay commercialization or impact profitability.
• Government Funding Restrictions: Government grants and contracts may impose unfavorable termination provisions, audit rights, intellectual property claims, and compliance requirements.

Geopolitical & External Risks

Geopolitical Exposure:

• Trade Relations: Exposure to trade tensions and conflicts (e.g., United States and China) affecting supply chains and costs.
• International Conflicts: Ongoing conflicts (e.g., Russia-Ukraine, Israel-Hamas war) could lead to global market disruption and impact operations. Natural Disasters & Public Health Crises:
• Operational Interruption: Vulnerability to natural disasters (earthquakes, wildfires), power loss, terrorist activity, and public health crises (pandemics), which could disrupt operations, clinical trials, and supply chains. Cidara Therapeutics, Inc. carries only limited business interruption insurance.

Innovation & Technology Leadership

Research & Development Focus: Cidara Therapeutics, Inc.'s R&D is solely focused on its proprietary Cloudbreak platform, which develops drug-Fc conjugate (DFC) immunotherapies. Core Technology Areas:

• DFC Immunotherapies: Designed to provide potent disease targeting activity and immune system engagement in a single, long-acting molecule.
• Influenza Program (CD388): Lead clinical-stage asset, a highly potent antiviral DFC for universal prevention and treatment of seasonal and pandemic influenza. Preclinical and early clinical studies have demonstrated broad-spectrum activity, a superior resistance profile, protection for high-risk populations, seasonal and pandemic readiness, and a long duration of action.
• Oncology Programs (CBO421): Developing DFCs to target single or multiple immune checkpoint pathways for solid tumors. CBO421 is a CD73 inhibitor designed to combine the strengths of small molecules and monoclonal antibodies, demonstrating activity and immunologic memory in murine tumor models.
• Innovation Pipeline: The company's strategy includes identifying additional DFCs for life-threatening diseases, with ongoing business development discussions for oncology DFC programs.

Intellectual Property Portfolio:

• Patent Strategy: Cidara Therapeutics, Inc. seeks to protect its proprietary position through patent protection in the U.S. and internationally.
• Patent Holdings:
  • CD388: The portfolio includes eight families of patents and patent applications. The first U.S. patent was received in December 2022, projected to expire in 2039 (plus any available patent term extension). The latest of the issued patents and any patents resulting from currently pending applications are expected to expire in 2044 (excluding additional term for patent term adjustments or extensions).
  • CBO421: The portfolio includes four families of patent applications. The latest of any patents resulting from currently pending applications are expected to expire in 2045 (excluding additional term for patent term adjustments or extensions).
• Licensing Programs: Not explicitly detailed for current IP, but the company reacquired CD388 rights through a license agreement.
• IP Litigation: No material disputes disclosed.
• Trade Secrets: The company relies on trade secret protection and confidentiality agreements to protect proprietary know-how not covered by patents.

Technology Partnerships:

• J&J Innovative Medicine (formerly Janssen Pharmaceuticals, Inc.): Cidara Therapeutics, Inc. previously partnered with Janssen Pharmaceuticals, Inc. for CD388 development and reacquired all rights to CD388 in April 2024.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: The company's future success depends on its ability to retain its senior management team and attract, retain, and motivate qualified personnel. A reduction in force was approved in September 2024, and the Chief Legal and Operating Officer and Chief Operating Officer separated from the company in January and February 2025, respectively.

Board Composition: The board of directors oversees cybersecurity risk management as part of its general oversight function. The audit committee receives quarterly updates from the Incident Response Team (IRT) concerning cybersecurity threats and risks, and the board receives an annual report from the IRT highlighting any significant cybersecurity threats. No further details on board independence, specific expertise areas, or committee structure are provided in the filing.

Human Capital Strategy

Workforce Composition:

• Total Employees: 38 (as of February 27, 2025).
• Geographic Distribution: Employees are primarily based in the U.S., with wholly-owned subsidiaries in England and Ireland.
• Skill Mix: 8 employees hold Ph.D. or M.D. degrees. 20 employees are engaged in research and development activities, and 18 are engaged in business development, finance, information systems, facilities, human resources, legal, or administrative support.

Talent Management: Acquisition & Retention:

• Hiring Strategy: Cidara Therapeutics, Inc. faces competition in recruiting and retaining qualified scientific, clinical, manufacturing, regulatory, quality assurance, and sales and marketing personnel.
• Retention Metrics: Not explicitly disclosed.
• Employee Value Proposition: Not explicitly detailed. Diversity & Development:
• Diversity Metrics: Not explicitly disclosed.
• Development Programs: Not explicitly detailed.
• Culture & Engagement: Not explicitly detailed.

Workforce Reduction: In September 2024, Cidara Therapeutics, Inc. approved a reduction in its workforce of 20 employees, representing approximately 30% of its total workforce. This action was taken to focus on the clinical development of CD388 and resulted in approximately $1.2 million in severance and employee benefits charges.

Business Cyclicality & Seasonality

Demand Patterns:

• Seasonal Trends: The lead product candidate, CD388, is intended for influenza prophylaxis, which is a seasonal respiratory infection. The CD388 Phase 2b NAVIGATE study was initiated during the 2024-25 Northern Hemisphere influenza season.
• Economic Sensitivity: The company's operations and financial condition are susceptible to broader macroeconomic conditions, including global pandemics, inflation, bank failures, labor shortages, supply chain disruptions, recession risks, and geopolitical conflicts.
• Industry Cycles: The biopharmaceutical industry is characterized by intense and dynamic competition and is subject to rapid changes.

Planning & Forecasting: Cidara Therapeutics, Inc. monitors macroeconomic conditions and attempts to adjust business plans to mitigate associated risks. No specific details on demand forecasting or inventory/capacity planning were provided.

Regulatory Environment & Compliance

Regulatory Framework: Cidara Therapeutics, Inc. is subject to extensive regulation by government authorities in the U.S. (federal, state, local) and other countries, covering all aspects of pharmaceutical product lifecycle, including research, development, testing, manufacturing, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring, reporting, import, and export. Industry-Specific Regulations:

• U.S. Drug Approval Process: Regulated by the U.S. Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act (FDCA) and Public Health Service (PHS) Act. This involves preclinical studies (Good Laboratory Practice, GLP), Investigational New Drug (IND) application submission, clinical trials (Good Clinical Practice, GCP, Institutional Review Board, IRB, approval, www.clinicaltrials.gov registration), Biologics License Application (BLA) submission, manufacturing facility inspections (current Good Manufacturing Practice, cGMP), and FDA review.
• Expedited Programs: CD388 has received Fast Track designation, which aims to facilitate development and expedite review for serious conditions with unmet medical needs, potentially allowing for more frequent FDA interactions and Priority Review eligibility.
• Post-Approval Requirements: Any approved products are subject to continuous FDA review, including submissions of promotional materials, safety and other post-marketing information and reports, registration and listing requirements, cGMP requirements for product facilities, quality assurance, and requirements regarding the distribution of samples to physicians. Post-approval requirements may include Risk Evaluation and Mitigation Strategies (REMS) and Phase 4 clinical trials.
• Healthcare Laws: The company's relationships with customers, healthcare professionals, and third-party payors are subject to federal and state anti-kickback laws, false claims laws (including the federal civil False Claims Act), data privacy and security laws (Health Insurance Portability and Accountability Act of 1996, Health Information Technology for Economic and Clinical Health Act, California Consumer Privacy Act of 2018), and transparency laws (Physician Payments Sunshine Act) regarding payments to healthcare providers. Non-compliance can lead to significant civil, criminal, and administrative penalties.
• International Compliance: Cidara Therapeutics, Inc. must comply with numerous and varying regulatory requirements in other countries for marketing products outside the U.S., including approval processes, price controls, and data localization laws.
• China Regulation: The pharmaceutical industry in China is highly regulated, requiring approvals from the National Medical Product Administration of China and the Ministry of Science and Technology for clinical trials involving Human Genetic Resources Materials or Information.

Trade & Export Controls:

• Export Restrictions: Cidara Therapeutics, Inc. is subject to U.S. export control and import laws and regulations (e.g., U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department’s Office of Foreign Assets Controls) and anti-corruption laws (U.S. Foreign Corrupt Practices Act of 1977, USA PATRIOT Act). Compliance is required for international markets and collaborations.
• Sanctions Compliance: Prohibitions on providing products and services to countries, governments, and persons targeted by U.S. sanctions.
• Proposed Legislation: Potential impact from legislation like the BIOSECURE Act, which could restrict work with certain Chinese biotechnology companies.

Legal Proceedings: Cidara Therapeutics, Inc. is not currently a party to any legal proceedings that, in the opinion of its management, are likely to have a material adverse effect on its business.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: Cidara Therapeutics, Inc. recorded no income tax expense for continuing operations for the year ended December 31, 2024, and $0.015 million for the year ended December 31, 2023.
• Geographic Tax Planning: The company's international business activities are subject to the tax laws of various jurisdictions, including the U.S.
• Tax Reform Impact:
  • IRC Section 174: The capitalization and amortization of R&D expenses (over five years for U.S. activities and 15 years for non-U.S. activities), effective January 1, 2022, impacts taxable income.
  • Inflation Reduction Act of 2022 (IRA): This act, among other things, extends enhanced subsidies for health insurance, eliminates the "donut hole" under the Medicare Part D program, and directs the U.S. Department of Health and Human Services (HHS) to negotiate the price of certain high-expenditure, single-source drugs, potentially impacting future revenues and tax liabilities.
  • Bayh-Dole Act "March-In Rights": A recent initiative to control prescription drug prices through the use of march-in rights under the Bayh-Dole Act, potentially including price as a factor, could affect the value of patent rights.
  • State-Level Legislation: State legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including importation programs (e.g., Florida’s Section 804 Importation Program), which could result in lower drug prices.

Tax Attributes:

• Net Operating Loss (NOL) Carryforwards: As of December 31, 2024, Cidara Therapeutics, Inc. had federal NOL carryforwards of approximately $202.8 million (portions begin to expire in 2035) and state NOL carryforwards of approximately $145.2 million (portions begin to expire in 2029).
• Tax Credit Carryforwards: The company holds federal R&D credit and orphan drug credit carryforwards totaling $14.1 million (begin to expire in 2038) and state R&D credit carryforwards totaling $6.2 million (mostly no expiration date).
• Valuation Allowance: A full valuation allowance of $120.9 million (federal) and $83.1 million (state) was recorded against deferred tax assets as of December 31, 2024, due to cumulative operating losses, indicating that the realization of these tax benefits is not more likely than not.
• IRC Sections 382 and 383: Future utilization of NOLs and tax credits may be subject to an annual limitation due to past or future "ownership changes."
• Uncertain Tax Positions: Unrecognized tax benefits of approximately $12.9 million as of December 31, 2024, primarily related to federal and state R&D credits.

Insurance & Risk Transfer

Risk Management Framework: Cidara Therapeutics, Inc. has implemented and maintains various information security processes designed to identify, assess, and manage material risks from cybersecurity threats to its critical computer networks, third-party hosted services, communications systems, hardware and software, and critical data. The Incident Response Team (IRT), comprising the Chief Legal and Operating Officer, Chief Financial and Business Officer, Senior Vice President, People and Culture, and Director, Information Technology (IT), along with external cybersecurity consultants, helps manage these risks. The audit committee receives quarterly updates on cybersecurity threats and risks, and the board of directors receives an annual report on significant cybersecurity threats.

Insurance Coverage:

• Product Liability Insurance: Cidara Therapeutics, Inc. maintains product liability insurance for its clinical trials. The company anticipates increasing its insurance coverage as it continues or expands clinical trials and if it successfully commercializes any products.
• Business Interruption Insurance: The company carries only limited business interruption insurance, which may not adequately compensate for actual losses from business interruptions.
• Environmental Liability/Toxic Tort Claims: Cidara Therapeutics, Inc. does not maintain insurance for environmental liability or toxic tort claims.

Risk Transfer Mechanisms:

• Contractual Risk Allocation: The company's vendor management program includes imposing information contractual obligations on third-party service providers to manage cybersecurity risks.
• Hedging Strategies: Not explicitly detailed in the filing.